Jean-Yves Blay
Director/Board Member en INNATE PHARMA .
Fortuna: 118 $ al 31/03/2024
Perfil
Jean-Yves Blay is currently an Independent Director at Transgene SA since 2022, the General Director at Centre Léon Bérard Lyon et Rhône-Alpes since 2014, and an Independent Member-Supervisory Board at Innate Pharma SA since 2017.
Previously, he served as the President of the European Organisation for Research & Treatment of Cancer from 2009 to 2012 and as the President of UNICANCER from 2019 to 2022.
He also held the position of Secretary-Oncology Commission at Académie Nationale de Médecine FCP.
Dr. Blay obtained his doctorate degree from Université Claude Bernard Lyon 1 in 1994.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INNATE PHARMA SA CLASS A
0.00% | 31/12/2022 | 50 ( 0.00% ) | 118 $ | 31/03/2024 |
Cargos activos de Jean-Yves Blay
| Empresas | Cargo | Inicio |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 13/12/2017 |
| TRANSGENE | Director/Board Member | 25/05/2022 |
| Centre Léon Bérard Lyon et Rhône-Alpes | Chief Executive Officer | 01/01/2014 |
Antiguos cargos conocidos de Jean-Yves Blay.
| Empresas | Cargo | Fin |
|---|---|---|
UNICANCER
 UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | President | 01/01/2022 |
| European Organisation for Research & Treatment of Cancer | President | 01/01/2012 |
| Académie Nationale de Médecine FCP | Corporate Officer/Principal | - |
Formación de Jean-Yves Blay.
| Université Claude Bernard Lyon 1 | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| TRANSGENE | Health Technology |
| INNATE PHARMA | Health Technology |
| Empresas privadas | 4 |
|---|---|
| European Organisation for Research & Treatment of Cancer | |
| Académie Nationale de Médecine FCP | Commercial Services |
UNICANCER
UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | Health Services |
| Centre Léon Bérard Lyon et Rhône-Alpes |
- Bolsa de valores
- Insiders
- Jean-Yves Blay
